PE20211816A1 - Proceso de elaboracion de alfa-cetoglutarato de calcio - Google Patents

Proceso de elaboracion de alfa-cetoglutarato de calcio

Info

Publication number
PE20211816A1
PE20211816A1 PE2021000354A PE2021000354A PE20211816A1 PE 20211816 A1 PE20211816 A1 PE 20211816A1 PE 2021000354 A PE2021000354 A PE 2021000354A PE 2021000354 A PE2021000354 A PE 2021000354A PE 20211816 A1 PE20211816 A1 PE 20211816A1
Authority
PE
Peru
Prior art keywords
alpha
ketoglutarate
salt
calcium
cetoglutarate
Prior art date
Application number
PE2021000354A
Other languages
English (en)
Inventor
David Eugene Pereira
Keshav Deo
Original Assignee
Ponce De Leon Health Designated Activity Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ponce De Leon Health Designated Activity Company filed Critical Ponce De Leon Health Designated Activity Company
Publication of PE20211816A1 publication Critical patent/PE20211816A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/418—Preparation of metal complexes containing carboxylic acid moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups

Abstract

En la presente se describen metodos y procesos para preparar sales de calcio de alfacetoglutarato. Este metodo comprende: a) poner en contacto el acido alfa-cetoglutarico con una sal de metal alcalino de un acido y agua para formar una solucion que tiene un pH en el intervalo de 5,0 a 11,9, formando asi una sal bis de alfa-cetoglutarato; y b) poner en contacto la sal bis de alfa-cetoglutarato con una sal de calcio y agua, formando asi alfa-cetoglutarato de calcio. De acuerdo con su papel en la generacion de energia a traves del ciclo de Krebs, el alfa-cetoglutarato es un importante regulador de la bioenergetica en las celulas y esta implicado como inhibidor de la subunidad ? de la ATP sintasa y como inhibidor indirecto de la quinasa mTOR, una consecuencia de la inhibicion parcial de la cadena de transporte de electrones mitocondrial.
PE2021000354A 2018-09-25 2019-09-23 Proceso de elaboracion de alfa-cetoglutarato de calcio PE20211816A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862736320P 2018-09-25 2018-09-25
PCT/US2019/052498 WO2020068705A1 (en) 2018-09-25 2019-09-23 Process of making calcium alpha-ketoglutarate

Publications (1)

Publication Number Publication Date
PE20211816A1 true PE20211816A1 (es) 2021-09-14

Family

ID=69952136

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000354A PE20211816A1 (es) 2018-09-25 2019-09-23 Proceso de elaboracion de alfa-cetoglutarato de calcio

Country Status (17)

Country Link
US (1) US11802103B2 (es)
EP (1) EP3856166A4 (es)
JP (1) JP2022502489A (es)
KR (1) KR20210065120A (es)
CN (1) CN112955139A (es)
AU (1) AU2019350699A1 (es)
BR (1) BR112021005668A2 (es)
CA (1) CA3112205A1 (es)
CL (1) CL2021000728A1 (es)
CO (1) CO2021004529A2 (es)
IL (1) IL281761A (es)
MX (1) MX2021003482A (es)
PE (1) PE20211816A1 (es)
PH (1) PH12021550403A1 (es)
SG (1) SG11202102204PA (es)
TW (1) TW202024013A (es)
WO (1) WO2020068705A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210065120A (ko) 2018-09-25 2021-06-03 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 칼슘 알파-케토글루타레이트의 제조 방법
CN112941116B (zh) * 2021-01-04 2022-12-02 上海朴颐化学科技有限公司 一种酶法制备α-酮戊二酸钙的方法
CN114105761A (zh) * 2021-11-19 2022-03-01 广东派特埃尔生物科技有限公司 一种α-酮戊二酸钠盐的合成工艺

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2776926A (en) 1955-08-04 1957-01-08 Eugene S Sharpe Preparation of alpha-ketoglutaric acid by serratia marcescens
US2917528A (en) 1956-08-24 1959-12-15 Victor Chemical Works Alkanolaminealkanephosphonic acids and salts thereof
US2841616A (en) * 1956-10-30 1958-07-01 Campbell Soup Co Process for the recovery of alpha-ketoglutaric acid
US3875304A (en) 1970-04-24 1975-04-01 Schlitz Brewing Co J Livestock feed composition and method of preparing the same
US4045585A (en) 1976-05-19 1977-08-30 Decel Corporation Flavored animal food compositions
DE3151196A1 (de) * 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
US6451341B1 (en) 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5646187A (en) 1992-05-20 1997-07-08 Ab Erik Vinnars Use of alpha-ketoglutarate
US6306430B1 (en) 1998-04-16 2001-10-23 The Iams Company Process for decreasing adiposity using vitamin a as a dietary supplement
US6905707B2 (en) 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
CO5140079A1 (es) 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
CA2431367C (en) 2000-12-20 2010-02-09 Alcon, Inc. Solution for removing cataracts via liquefracture
AU2005240257B2 (en) * 2004-05-06 2011-11-24 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
PL368572A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
US20090005437A1 (en) 2004-08-09 2009-01-01 Eyal Gottlieb Alpha-Ketoglutarates and Their Use as Therapeutic Agents
AU2005316295B2 (en) 2004-12-17 2012-03-22 Alan B. Cash Method for extending lifespan and delaying the onset of age-related disease
US20060234250A1 (en) 2005-04-15 2006-10-19 Powers Ralph W Iii Methods of screening and compositions for life span modulators
US20070135376A1 (en) 2005-06-20 2007-06-14 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
US20070105942A1 (en) 2005-11-08 2007-05-10 Heuer Marvin A Supplemental dietary composition for turning on anabolic switches in muscle, stimulating and/or optimizing protein synthesis, and/or potently signaling muscle building and/or growth via molecular pathways
US8367121B2 (en) 2005-11-23 2013-02-05 Florida A & M University Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
PL379512A1 (pl) 2006-04-21 2007-10-29 Sgp & Sons Ab Nowe metody i ich zastosowanie
PL226695B1 (pl) 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
US8815306B2 (en) 2007-03-19 2014-08-26 Metaproteomics, Llc Methods and compositions for promoting bone and joint health
EP2173336B1 (en) 2007-07-02 2016-03-30 Protista Biotechnology AB Alpha-ketoglutaric acid for use in the treatment of hypertension or pulmonary hypertension
EP2033623A1 (en) 2007-09-07 2009-03-11 Cutech S.R.L. Compositions comprising ornithine ketoglutarate (OKG)
CN101759553A (zh) 2008-11-21 2010-06-30 扬子江药业集团北京海燕药业有限公司 α-酮酸钙的制备方法
DE102009016119A1 (de) 2009-04-03 2010-10-14 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren zur Unterstützung der Diabetestherapie
JP5852557B2 (ja) 2009-04-10 2016-02-03 チー，ハイヤン 新規抗老化剤及びそれらを同定する方法
EA201101519A1 (ru) 2009-05-11 2012-10-30 БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EP2434908A2 (en) 2009-05-28 2012-04-04 The IAMS Company Pet food in the form of a coated kibble
AU2010258356B2 (en) 2009-06-12 2017-01-19 Generex Pharmaceuticals, Inc. Compositions and methods for prevention and treatment of brain diseases and conditions
KR20170010442A (ko) 2009-06-30 2017-01-31 더만 바이오메디슨 코. 엘티디. 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물
US9283257B2 (en) 2009-11-12 2016-03-15 Nox Technologies, Inc. Compositions comprising solanum tuberosum for lowering cytosolic NADH level to mimic calorie restriction
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
SG194065A1 (en) 2011-04-18 2013-11-29 Nestec Sa Nutritional compositions having alpha-hica and alpha-ketoglutarate
WO2012174537A2 (en) 2011-06-16 2012-12-20 President And Fellows Of Harvard College Small molecule screening for mouse satellite cell proliferation
US9532997B2 (en) 2012-04-03 2017-01-03 Whitehead Institute For Biomedical Research Compositions and methods for promoting intestinal stem cell function
ITBO20120226A1 (it) 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
CA2884592C (en) 2012-09-19 2021-08-31 Grespo Ab Compositions for improvement of brain function
CN102976927A (zh) * 2012-12-26 2013-03-20 天津天成制药有限公司 α-酮戊二酸钙的制备方法
CA2896646A1 (en) 2012-12-27 2014-07-03 Hayashibara Co., Ltd. Skin-exterior anti-ageing composition and production method therefor
US20150328176A1 (en) 2013-01-25 2015-11-19 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
US9511057B2 (en) 2013-03-15 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating denervation-induced muscle atrophy
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
US20160263092A1 (en) 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
CN106163513A (zh) 2014-02-12 2016-11-23 加利福尼亚大学董事会 用于治疗衰老和与年龄相关的疾病和症状的组合物和方法
WO2015171723A1 (en) 2014-05-06 2015-11-12 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
US10729668B2 (en) 2014-06-30 2020-08-04 The Regents Of The University Of California Ketobutyrate compounds and compositions for treating age-related symptoms and diseases
IL294063A (en) 2014-07-29 2022-08-01 Shenzhen Hightide Biopharmaceutical Ltd Salts of berberic acid, salts of ursodeoxycholic acid and their combinations, methods for their preparation and their uses
WO2016019224A1 (en) 2014-07-31 2016-02-04 Indiana University Research And Technology Corporation Antithetical regulation of endothelial ace and ace2 by brg1-foxm1 complex underlies pathological cardiac hypertrophy
EP3280712A4 (en) 2015-04-06 2019-01-09 Shenzhen Hightide Biopharmaceutical, Ltd. CONJUGATED COMPOUNDS OF URSODESOXYCHOLIC ACID, BERBERIN OR L-CARNITINE, AND COMPOSITIONS AND METHODS COMPRISING THE SAME
RU2017145692A (ru) 2015-06-10 2019-07-10 Элизиум Хелт, Инк. Композиции никотинамида рибозида и птеростильбена и способы лечения заболеваний кожи
US20180193458A1 (en) 2015-07-08 2018-07-12 Unity Biotechnology, Inc. Compositions and methods for treating senescence-associated diseases and disorders
US20190247342A1 (en) 2016-09-30 2019-08-15 The Regents Of The University Of California Alpha-Ketobutyrate, 2-Hydroxybutyrate, and Alpha-Ketoglutarate for Stimulating Hair Growth
PL231635B1 (pl) * 2017-01-03 2019-03-29 Politechnika Poznanska Sposób produkcji kwasu alfa-ketoglutarowego (AKG) z jednoskładnikowych roztworów wodnych
MX2017004010A (es) 2017-03-27 2018-02-09 Antonio Hernandez Miramontes Jorge Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.
SG10202107237SA (en) 2017-04-25 2021-08-30 Buck Inst Res Aging Formulations for extending lifespan and healthspan
US20200253907A1 (en) 2017-08-21 2020-08-13 The Regents Of The University Of California Compositions and Methods for Treating Neurodegenerative Diseases
KR20210065120A (ko) 2018-09-25 2021-06-03 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 칼슘 알파-케토글루타레이트의 제조 방법
WO2020086733A1 (en) 2018-10-24 2020-04-30 Ponce De Leon Health Designated Activity Company Nicotinamide riboside compositions for healthspan extension
AU2020292278A1 (en) 2019-06-10 2022-01-06 Ponce De Leon Health Designated Activity Company Sustained-release compositions of alpha-ketoglutarate
EP3980000A4 (en) 2019-06-10 2023-06-21 Buck Institute for Research on Aging METHODS AND COMPOSITIONS FOR MODIFYING A SECRETORY PHENOTYPE ASSOCIATED WITH SENESCENCE
US20230255912A1 (en) 2020-07-02 2023-08-17 Ponce De Leon Health Designated Activity Company Compositions and methods for treating crp-mediated diseases

Also Published As

Publication number Publication date
EP3856166A4 (en) 2022-06-22
WO2020068705A1 (en) 2020-04-02
KR20210065120A (ko) 2021-06-03
EP3856166A1 (en) 2021-08-04
MX2021003482A (es) 2021-06-18
IL281761A (en) 2021-05-31
US11802103B2 (en) 2023-10-31
JP2022502489A (ja) 2022-01-11
AU2019350699A1 (en) 2021-04-08
PH12021550403A1 (en) 2021-10-04
TW202024013A (zh) 2020-07-01
CN112955139A (zh) 2021-06-11
CO2021004529A2 (es) 2021-04-30
US20210371368A1 (en) 2021-12-02
BR112021005668A2 (pt) 2021-06-22
CL2021000728A1 (es) 2021-10-22
SG11202102204PA (en) 2021-04-29
CA3112205A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
PE20211816A1 (es) Proceso de elaboracion de alfa-cetoglutarato de calcio
CL2016001285A1 (es) Técnicas de control para plantas de energía fotovoltaicas
AR086702A1 (es) Proceso para la produccion de carbonato de calcio precipitado, carbonato de calcio precipitado y sus usos
CL2013002797A1 (es) Método para la fabricación de un fertilizante; sistema de fabricacion de un fertilizante; fertilizante; proceso de preparación de fertilizante
EA201001118A1 (ru) Непрерывный способ получения алканоламидов жирных кислот
WO2013041674A3 (en) Process for processing a lignocellulosic material by dilute acid pretreatment
AR116719A1 (es) Microbiorreactor de flujo continuo
CL2022003197A1 (es) Sistema de producción y transporte de hidrógeno
ES2634683T3 (es) Método de preparación de cisteína o de un derivado de la misma utilizando una nueva O-fosfoserina sulfhidrilasa
CL2020000152A1 (es) Método para mejorar la eficiencia de una planta de gas de síntesis de amoníaco.
AR109574A1 (es) Método para la fabricación de cloruro de litio y método para la fabricación de carbonato de litio
MY171453A (en) Anti-corrosive agent for boilers
CL2019000016A1 (es) Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble.
AR102805A1 (es) Método para purificación de biogás y producción de sulfato de amonio
CL2009000285A1 (es) Sistema para producir energia termosolar formado con un a isla artificial flotante con una fuente de energia primaria usada en un ciclo clausius rankine; presenta al menos un tanque de almacenaje de vapor conectado a una pluiralidad de colectores solares, el tanque se localiza bajo el nivel del mar compensando su presion interior.
AR084183A1 (es) Procedimiento para la produccion de oxido de cromo (iii)
MX2020007283A (es) Derivados de acido 3-fenil-4-hexinoico como agonistas del receptor acoplado a la proteina g-40.
CO2024000221A2 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MX2017004984A (es) Soluciones de sales de metal trialcalino de acidos aminocarboxilicos, su produccion y uso.
ES2496447T3 (es) Procedimiento de preparación de un aminoácido a partir de 2-aminobutirolactona
MX2021015159A (es) Formulacion de inhibidores de corrosion para pozos de reinyeccion geotermica.
PE20190163A1 (es) Planta de fabricacion para nitrato de amonio y un proceso para iniciarlo
CL2010000052A1 (es) Metodo para inhibir la respuesta al etileno en una planta que comprende aplicar al menos en una parte de la planta, sales del acido 3-(1-ciclopropenil)-propanoico; sales de na, li, mg, ca, k, amonio y derivados de sulfato y/o fosfato del acido 3-(1-ciclopropenil)-propanoico y soluciones acuosas que las contienen.
CO2018001322A1 (es) Método para fortalecer y curvar capas de vidrio
AR110384A1 (es) Proceso para la fabricación de derivados de diazepina